{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T11:59:13Z","timestamp":1769083153895,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23FC1030"],"award-info":[{"award-number":["23FC1030"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.resinv.2025.04.008","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T13:13:41Z","timestamp":1744895621000},"page":"481-487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characteristics, clinical findings, and treatment of idiopathic pulmonary fibrosis in Japanese patients registered with a medical subsidy system for intractable diseases"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0573-9344","authenticated-orcid":false,"given":"Hirotaka","family":"Nishikiori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1698-2304","authenticated-orcid":false,"given":"Reoto","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Kondoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2025.04.008_bib1","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1164\/rccm.201403-0566OC","article-title":"Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences","volume":"190","author":"Natsuizaka","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.04.008_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.resinv.2014.08.003","article-title":"Usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment","volume":"53","author":"Homma","year":"2015","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2025.04.008_bib3","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/resp.13138","article-title":"Disease severity staging system for idiopathic pulmonary fibrosis in Japan","volume":"22","author":"Kondoh","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2025.04.008_bib4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1164\/ajrccm.165.3.2107134","article-title":"Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases","volume":"165","author":"Ohnishi","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.04.008_bib5","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1164\/ajrccm.162.3.9910080","article-title":"Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent","volume":"162","author":"Takahashi","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.04.008_bib6","first-page":"759","article-title":"Nationwide epidemiological survey of patients with idiopathic interstitial pneumonias using clinical personal records","volume":"45","author":"Ohno","year":"2007","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"10.1016\/j.resinv.2025.04.008_bib7","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.04.008_bib8","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.04.008_bib9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1440-1843.2006.00834.x","article-title":"Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis","volume":"11","author":"Yokoyama","year":"2006","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2025.04.008_bib10","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.apmr.2014.01.016","article-title":"Evaluation of activity limitation in patients with idiopathic pulmonary fibrosis grouped according to Medical Research Council dyspnea grade","volume":"95","author":"Kozu","year":"2014","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.resinv.2025.04.008_bib11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.rmed.2004.09.005","article-title":"Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor?","volume":"99","author":"Nishiyama","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2025.04.008_bib12","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/thx.2010.139121","article-title":"Development and validity testing of an IPF-specific version of the St George's respiratory questionnaire","volume":"65","author":"Yorke","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2025.04.008_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-020-1298-1","article-title":"Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS\u00ae trials","volume":"21","author":"Kreuter","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2025.04.008_bib14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12931-017-0503-3","article-title":"The St. George\u2019s respiratory questionnaire as a prognostic factor in IPF","volume":"18","author":"Furukawa","year":"2017","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2025.04.008_bib15","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2169\/internalmedicine.46.6218","article-title":"Health-related quality of life in patients with idiopathic pulmonary fibrosis-cross-sectional and longitudinal study","volume":"46","author":"Tomioka","year":"2007","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2025.04.008_bib16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2169\/internalmedicine.44.196","article-title":"Reassessment of the classification of the severity in idiopathic pulmonary fibrosis using SF-36 questionnaire","volume":"44","author":"Ohno","year":"2005","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2025.04.008_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00084-2017","article-title":"mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis","volume":"3","author":"Rajala","year":"2017","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.resinv.2025.04.008_bib18","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.04.008_bib19","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.04.008_bib20","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.resinv.2022.08.004","article-title":"Current treatment status of patients with idiopathic pulmonary fibrosis in Japan based on a claims database analysis","volume":"60","author":"Suda","year":"2022","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2025.04.008_bib21","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525000504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525000504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T23:50:02Z","timestamp":1749599402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534525000504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2212534525000504"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2025.04.008","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics, clinical findings, and treatment of idiopathic pulmonary fibrosis in Japanese patients registered with a medical subsidy system for intractable diseases","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2025.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}